Summary
Global Markets Direct’s, ‘Insulin Resistance - Pipeline Review, H1 2016’, provides an overview of the Insulin Resistance pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
- The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects
- The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Insulin Resistance
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AUS Bio Limited
Genentech, Inc.
Genfit SA
GlaxoSmithKline Plc
Hadasit Medical Research Services & Development Ltd
Mertiva AB
Prometheon Pharma, LLC
Sanofi
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Insulin Resistance Overview 7
Therapeutics Development 8
Pipeline Products for Insulin Resistance - Overview 8
Pipeline Products for Insulin Resistance - Comparative Analysis 9
Insulin Resistance - Therapeutics under Development by Companies 10
Insulin Resistance - Therapeutics under Investigation by Universities/Institutes 11
Insulin Resistance - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Insulin Resistance - Products under Development by Companies 14
Insulin Resistance - Products under Investigation by Universities/Institutes 15
Insulin Resistance - Companies Involved in Therapeutics Development 16
AUS Bio Limited 16
Genentech, Inc. 17
Genfit SA 18
GlaxoSmithKline Plc 19
Hadasit Medical Research Services & Development Ltd 20
Mertiva AB 21
Prometheon Pharma, LLC 22
Sanofi 23
Insulin Resistance - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BFKB-8488A - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
elafibranor - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
englerin A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
FC-98 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MD-960 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Peptide for Obesity and Insulin Resistance - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SAR-088 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule for Hypertension and Insulin Resistance - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SYM-401 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Synthetic Peptide to Inhibit Protein Kinase C for Type-2 diabetes and Insulin Resistance - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Insulin Resistance - Recent Pipeline Updates 52
Insulin Resistance - Dormant Projects 58
Insulin Resistance - Product Development Milestones 60
Featured News & Press Releases 60
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62
List of Tables
Number of Products under Development for Insulin Resistance, H1 2016 8
Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Insulin Resistance - Pipeline by AUS Bio Limited, H1 2016 16
Insulin Resistance - Pipeline by Genentech, Inc., H1 2016 17
Insulin Resistance - Pipeline by Genfit SA, H1 2016 18
Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H1 2016 19
Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 20
Insulin Resistance - Pipeline by Mertiva AB, H1 2016 21
Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2016 22
Insulin Resistance - Pipeline by Sanofi, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2016 52
Insulin Resistance - Dormant Projects, H1 2016 58
Insulin Resistance - Dormant Projects (Contd..1), H1 2016 59
List of Figures
Number of Products under Development for Insulin Resistance, H1 2016 8
Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
